Pushcom Bio is a high-tech enterprise based on in vitro diagnosis (IVD). The company uses the world’s leading microfluidic disk chip platform technology, combined with the original micro whole blood separation function, to develop coagulation, immunity, biochemistry, Molecular diagnostic kits and new supporting detection systems. Recently, Pushkang Bio completed the C+ round of financing of over 100 million yuan. This round of financing was led by October Capital, followed by Jiji Venture Capital and Changan Huitong, and the old shareholder Yinglian Health continued to increase its investment. This round of financing will further accelerate the pipeline expansion of Pushcon’s centrifugal microfluidic platform products focusing on critical illness + chronic disease management, and accelerate the overseas sales layout. .
This article is reproduced from: https://www.itjuzi.com/investevent/13616968
This site is for inclusion only, and the copyright belongs to the original author.